Molecular Monitoring after Autologous Stem Cell Transplantation and Preemptive Rituximab Treatment of Molecular Relapse; Results from the Nordic Mantle Cell Lymphoma Studies (MCL2 and MCL3) with Median Follow-Up of 8.5 Years

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

Molecular Monitoring after Autologous Stem Cell Transplantation and Preemptive Rituximab Treatment of Molecular Relapse; Results from the Nordic Mantle Cell Lymphoma Studies (MCL2 and MCL3) with Median Follow-Up of 8.5 Years. / Kolstad, Arne; Pedersen, Lone Bredo; Eskelund, Christian W.; Husby, Simon; Grønbæk, Kirsten; Jerkeman, Mats; Laurell, Anna; Räty, Riikka; Elonen, Erkki; Andersen, Niels Smedegaard; Brown, Peter de Nully; Kimby, Eva; Bentzen, Hans; Sundström, Christer; Ehinger, Mats; Karjalainen-Lindsberg, Marja Liisa; Delabie, Jan; Ralfkiær, Elisabeth; Fagerli, Unn Merete; Nilsson-Ehle, Herman; Lauritzsen, Grete Fossum; Kuittinen, Outi; Niemann, Carsten; Geisler, Christian Hartman; the Nordic Lymphoma Group.

In: Biology of Blood and Marrow Transplantation, Vol. 23, No. 3, 03.2017, p. 428-435.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Kolstad, A, Pedersen, LB, Eskelund, CW, Husby, S, Grønbæk, K, Jerkeman, M, Laurell, A, Räty, R, Elonen, E, Andersen, NS, Brown, PDN, Kimby, E, Bentzen, H, Sundström, C, Ehinger, M, Karjalainen-Lindsberg, ML, Delabie, J, Ralfkiær, E, Fagerli, UM, Nilsson-Ehle, H, Lauritzsen, GF, Kuittinen, O, Niemann, C, Geisler, CH & the Nordic Lymphoma Group 2017, 'Molecular Monitoring after Autologous Stem Cell Transplantation and Preemptive Rituximab Treatment of Molecular Relapse; Results from the Nordic Mantle Cell Lymphoma Studies (MCL2 and MCL3) with Median Follow-Up of 8.5 Years', Biology of Blood and Marrow Transplantation, vol. 23, no. 3, pp. 428-435. https://doi.org/10.1016/j.bbmt.2016.12.634

APA

Kolstad, A., Pedersen, L. B., Eskelund, C. W., Husby, S., Grønbæk, K., Jerkeman, M., Laurell, A., Räty, R., Elonen, E., Andersen, N. S., Brown, P. D. N., Kimby, E., Bentzen, H., Sundström, C., Ehinger, M., Karjalainen-Lindsberg, M. L., Delabie, J., Ralfkiær, E., Fagerli, U. M., ... the Nordic Lymphoma Group (2017). Molecular Monitoring after Autologous Stem Cell Transplantation and Preemptive Rituximab Treatment of Molecular Relapse; Results from the Nordic Mantle Cell Lymphoma Studies (MCL2 and MCL3) with Median Follow-Up of 8.5 Years. Biology of Blood and Marrow Transplantation, 23(3), 428-435. https://doi.org/10.1016/j.bbmt.2016.12.634

Vancouver

Kolstad A, Pedersen LB, Eskelund CW, Husby S, Grønbæk K, Jerkeman M et al. Molecular Monitoring after Autologous Stem Cell Transplantation and Preemptive Rituximab Treatment of Molecular Relapse; Results from the Nordic Mantle Cell Lymphoma Studies (MCL2 and MCL3) with Median Follow-Up of 8.5 Years. Biology of Blood and Marrow Transplantation. 2017 Mar;23(3):428-435. https://doi.org/10.1016/j.bbmt.2016.12.634

Author

Kolstad, Arne ; Pedersen, Lone Bredo ; Eskelund, Christian W. ; Husby, Simon ; Grønbæk, Kirsten ; Jerkeman, Mats ; Laurell, Anna ; Räty, Riikka ; Elonen, Erkki ; Andersen, Niels Smedegaard ; Brown, Peter de Nully ; Kimby, Eva ; Bentzen, Hans ; Sundström, Christer ; Ehinger, Mats ; Karjalainen-Lindsberg, Marja Liisa ; Delabie, Jan ; Ralfkiær, Elisabeth ; Fagerli, Unn Merete ; Nilsson-Ehle, Herman ; Lauritzsen, Grete Fossum ; Kuittinen, Outi ; Niemann, Carsten ; Geisler, Christian Hartman ; the Nordic Lymphoma Group. / Molecular Monitoring after Autologous Stem Cell Transplantation and Preemptive Rituximab Treatment of Molecular Relapse; Results from the Nordic Mantle Cell Lymphoma Studies (MCL2 and MCL3) with Median Follow-Up of 8.5 Years. In: Biology of Blood and Marrow Transplantation. 2017 ; Vol. 23, No. 3. pp. 428-435.

Bibtex

@article{4a8c155ee68a4d88a77cc799a58874a3,
title = "Molecular Monitoring after Autologous Stem Cell Transplantation and Preemptive Rituximab Treatment of Molecular Relapse; Results from the Nordic Mantle Cell Lymphoma Studies (MCL2 and MCL3) with Median Follow-Up of 8.5 Years",
abstract = "The main objectives of the present study were to monitor minimal residual disease (MRD) in the bone marrow of patients with mantle cell lymphoma (MCL) to predict clinical relapse and guide preemptive treatment with rituximab. Among the patients enrolled in 2 prospective trials by the Nordic Lymphoma Group, 183 who had completed autologous stem cell transplantation (ASCT) and in whom an MRD marker had been obtained were included in our analysis. Fresh samples of bone marrow were analyzed for MRD by a combined standard nested and quantitative real-time PCR assay for Bcl-1/immunoglobulin heavy chain gene (IgH) and clonal IgH rearrangements. Significantly shorter progression-free survival (PFS) and overall survival (OS) was demonstrated for patients who were MRD positive pre-ASCT (54 patients) or in the first analysis post-ASCT (23 patients). The median PFS was only 20 months in those who were MRD-positive in the first sample post-ASCT, compared with 142 months in the MRD-negative group (P < .0001). OS was 75% at 10 years and median not reached in the MRD-negative group, compared with only 35 months in the MRD-positive group (P < .0001). Of the 86 patients (47%) who remained in continuous molecular remission, 73% were still in clinical remission after 10 years. For all patients, the median time from ASCT to first molecular relapse was 55 months, with a continuous occurrence of late molecular relapses. Fifty-eight patients who experienced MRD relapse received rituximab as preemptive treatment on 1 or more occasions, and in this group, the median time from first molecular relapse to clinical relapse was 55 months. In most cases, rituximab converted patients to MRD negativity (87%), but many patients became MRD-positive again later during follow-up (69%). By multivariate analysis, high-risk Mantle Cell Lymphoma International Prognostic Index score and positive MRD status pre-ASCT predicted early molecular relapse. In conclusion, preemptive rituximab treatment converts patients to MRD negativity and likely postpones clinical relapse. Molecular monitoring offers an opportunity to select some patients for therapeutic intervention and to avoid unnecessary treatment in others. MRD-positive patients in the first analysis post-ASCT have a dismal prognosis and thus are in need of novel strategies.",
keywords = "Autologous stem cell transplantation, Mantle cell lymphoma, Minimal residual disease, Preemptive rituximab",
author = "Arne Kolstad and Pedersen, {Lone Bredo} and Eskelund, {Christian W.} and Simon Husby and Kirsten Gr{\o}nb{\ae}k and Mats Jerkeman and Anna Laurell and Riikka R{\"a}ty and Erkki Elonen and Andersen, {Niels Smedegaard} and Brown, {Peter de Nully} and Eva Kimby and Hans Bentzen and Christer Sundstr{\"o}m and Mats Ehinger and Karjalainen-Lindsberg, {Marja Liisa} and Jan Delabie and Elisabeth Ralfki{\ae}r and Fagerli, {Unn Merete} and Herman Nilsson-Ehle and Lauritzsen, {Grete Fossum} and Outi Kuittinen and Carsten Niemann and Geisler, {Christian Hartman} and {the Nordic Lymphoma Group}",
year = "2017",
month = mar,
doi = "10.1016/j.bbmt.2016.12.634",
language = "English",
volume = "23",
pages = "428--435",
journal = "Biology of Blood and Marrow Transplantation",
issn = "1083-8791",
publisher = "Elsevier",
number = "3",

}

RIS

TY - JOUR

T1 - Molecular Monitoring after Autologous Stem Cell Transplantation and Preemptive Rituximab Treatment of Molecular Relapse; Results from the Nordic Mantle Cell Lymphoma Studies (MCL2 and MCL3) with Median Follow-Up of 8.5 Years

AU - Kolstad, Arne

AU - Pedersen, Lone Bredo

AU - Eskelund, Christian W.

AU - Husby, Simon

AU - Grønbæk, Kirsten

AU - Jerkeman, Mats

AU - Laurell, Anna

AU - Räty, Riikka

AU - Elonen, Erkki

AU - Andersen, Niels Smedegaard

AU - Brown, Peter de Nully

AU - Kimby, Eva

AU - Bentzen, Hans

AU - Sundström, Christer

AU - Ehinger, Mats

AU - Karjalainen-Lindsberg, Marja Liisa

AU - Delabie, Jan

AU - Ralfkiær, Elisabeth

AU - Fagerli, Unn Merete

AU - Nilsson-Ehle, Herman

AU - Lauritzsen, Grete Fossum

AU - Kuittinen, Outi

AU - Niemann, Carsten

AU - Geisler, Christian Hartman

AU - the Nordic Lymphoma Group

PY - 2017/3

Y1 - 2017/3

N2 - The main objectives of the present study were to monitor minimal residual disease (MRD) in the bone marrow of patients with mantle cell lymphoma (MCL) to predict clinical relapse and guide preemptive treatment with rituximab. Among the patients enrolled in 2 prospective trials by the Nordic Lymphoma Group, 183 who had completed autologous stem cell transplantation (ASCT) and in whom an MRD marker had been obtained were included in our analysis. Fresh samples of bone marrow were analyzed for MRD by a combined standard nested and quantitative real-time PCR assay for Bcl-1/immunoglobulin heavy chain gene (IgH) and clonal IgH rearrangements. Significantly shorter progression-free survival (PFS) and overall survival (OS) was demonstrated for patients who were MRD positive pre-ASCT (54 patients) or in the first analysis post-ASCT (23 patients). The median PFS was only 20 months in those who were MRD-positive in the first sample post-ASCT, compared with 142 months in the MRD-negative group (P < .0001). OS was 75% at 10 years and median not reached in the MRD-negative group, compared with only 35 months in the MRD-positive group (P < .0001). Of the 86 patients (47%) who remained in continuous molecular remission, 73% were still in clinical remission after 10 years. For all patients, the median time from ASCT to first molecular relapse was 55 months, with a continuous occurrence of late molecular relapses. Fifty-eight patients who experienced MRD relapse received rituximab as preemptive treatment on 1 or more occasions, and in this group, the median time from first molecular relapse to clinical relapse was 55 months. In most cases, rituximab converted patients to MRD negativity (87%), but many patients became MRD-positive again later during follow-up (69%). By multivariate analysis, high-risk Mantle Cell Lymphoma International Prognostic Index score and positive MRD status pre-ASCT predicted early molecular relapse. In conclusion, preemptive rituximab treatment converts patients to MRD negativity and likely postpones clinical relapse. Molecular monitoring offers an opportunity to select some patients for therapeutic intervention and to avoid unnecessary treatment in others. MRD-positive patients in the first analysis post-ASCT have a dismal prognosis and thus are in need of novel strategies.

AB - The main objectives of the present study were to monitor minimal residual disease (MRD) in the bone marrow of patients with mantle cell lymphoma (MCL) to predict clinical relapse and guide preemptive treatment with rituximab. Among the patients enrolled in 2 prospective trials by the Nordic Lymphoma Group, 183 who had completed autologous stem cell transplantation (ASCT) and in whom an MRD marker had been obtained were included in our analysis. Fresh samples of bone marrow were analyzed for MRD by a combined standard nested and quantitative real-time PCR assay for Bcl-1/immunoglobulin heavy chain gene (IgH) and clonal IgH rearrangements. Significantly shorter progression-free survival (PFS) and overall survival (OS) was demonstrated for patients who were MRD positive pre-ASCT (54 patients) or in the first analysis post-ASCT (23 patients). The median PFS was only 20 months in those who were MRD-positive in the first sample post-ASCT, compared with 142 months in the MRD-negative group (P < .0001). OS was 75% at 10 years and median not reached in the MRD-negative group, compared with only 35 months in the MRD-positive group (P < .0001). Of the 86 patients (47%) who remained in continuous molecular remission, 73% were still in clinical remission after 10 years. For all patients, the median time from ASCT to first molecular relapse was 55 months, with a continuous occurrence of late molecular relapses. Fifty-eight patients who experienced MRD relapse received rituximab as preemptive treatment on 1 or more occasions, and in this group, the median time from first molecular relapse to clinical relapse was 55 months. In most cases, rituximab converted patients to MRD negativity (87%), but many patients became MRD-positive again later during follow-up (69%). By multivariate analysis, high-risk Mantle Cell Lymphoma International Prognostic Index score and positive MRD status pre-ASCT predicted early molecular relapse. In conclusion, preemptive rituximab treatment converts patients to MRD negativity and likely postpones clinical relapse. Molecular monitoring offers an opportunity to select some patients for therapeutic intervention and to avoid unnecessary treatment in others. MRD-positive patients in the first analysis post-ASCT have a dismal prognosis and thus are in need of novel strategies.

KW - Autologous stem cell transplantation

KW - Mantle cell lymphoma

KW - Minimal residual disease

KW - Preemptive rituximab

U2 - 10.1016/j.bbmt.2016.12.634

DO - 10.1016/j.bbmt.2016.12.634

M3 - Journal article

C2 - 28039078

AN - SCOPUS:85009455648

VL - 23

SP - 428

EP - 435

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

SN - 1083-8791

IS - 3

ER -

ID: 189699111